Related Posts

See All

Tralesinidase Alfa Pre-Clinical Publications

Allievex obtained an exclusive worldwide license for tralesinidase alfa from BioMarin (BMN 250) in October 2019 for the treatment of patients with Sanfilippo syndrome type B. Review pre-clinical publi

Screen Shot 2021-01-25 at 4.58.05 PM.png

CONNECT

Allievex Corporation

P.O. Box 1056

Marblehead, MA 01945

USA